Abstract: The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFN?, which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents.
Type:
Application
Filed:
September 15, 2003
Publication date:
June 15, 2006
Applicant:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOETCHNOLOGIES
Inventors:
Christophe de Romeuf, Arnaud Glacet, Jacques Lirochon, Dominique Bourel